Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-2280-2013

ABX PENTRA Calcium CP Reagent, Model # A11A01633 Calcium plays an essential role in many cell functions: intracellularly in muscle contraction and glycogen metabolism, extracellularly, in bone mineralization, in blood coagulation and in transmission of nerve impulses. Calcium is present in plasma in three forms: free, bound to proteins or complexed with anions as phosphate, citrate and bicarbonate. Under physiological conditions, calcium balance is determined by the relationship between calcium intake and calcium absorption and excretion. Urinary excretion is an important determinant of calcium retention in the body. Decreased total calcium levels can be associated with diseases of the bone apparatus (especially osteoporosis), kidney diseases (especially under dialysis), defective intestinal absorption and hypoparathyroidism. Increased total calcium can be measured in hyperparathyroidism, malignant diseases with metastases and sarcoidosis. Calcium measurements also help in monitoring of calcium supplementation mainly in the prevention of osteoporosis.

Publicado el 2 de octubre de 2013 · Inicio del retiro: 6 de septiembre de 2013

Resumen

FDA registra el retiro Z-2280-2013 de dispositivos médicos de Clase III, publicado el 2 de octubre de 2013 e iniciado el 6 de septiembre de 2013. Empresa responsable: Horiba Instruments, Inc dba Horiba Medical; Estado: Finalizado; Cantidad reportada: 2,658 units ( 1240 US 1418 OUS ); Lote: Lot/Serial #(s): 014664503. La Clase III indica que no es probable que el producto cause consecuencias adversas para la salud.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

HORIBA Medical is informing all PENTRA 200 and PENTRA 400 customers of a potential for reporting incorrect calcium results when using the ABX PENTRA CALCIUM CP reagent.

Qué hacer

Voluntary: Firm initiated · Letter

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Horiba Instruments, Inc dba Horiba Medical
Distribuidor
Worldwide Distribution - USA including the country of Canada.
Lote
Lot/Serial #(s): 014664503
Clasificación de riesgo
Class III
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿ABX PENTRA Calcium CP Reagent, Model # A11A01633 Calcium plays an essential role in many cell functions: intracellularly in muscle contraction and glycogen metabolism, extracellularly, in bone mineralization, in blood coagulation and in transmission of nerve impulses. Calcium is present in plasma in three forms: free, bound to proteins or complexed with anions as phosphate, citrate and bicarbonate. Under physiological conditions, calcium balance is determined by the relationship between calcium intake and calcium absorption and excretion. Urinary excretion is an important determinant of calcium retention in the body. Decreased total calcium levels can be associated with diseases of the bone apparatus (especially osteoporosis), kidney diseases (especially under dialysis), defective intestinal absorption and hypoparathyroidism. Increased total calcium can be measured in hyperparathyroidism, malignant diseases with metastases and sarcoidosis. Calcium measurements also help in monitoring of calcium supplementation mainly in the prevention of osteoporosis. fue retirado del mercado?

Sí. FDA publicó el retiro Z-2280-2013 el 2 de octubre de 2013. Peligro reportado: HORIBA Medical is informing all PENTRA 200 and PENTRA 400 customers of a potential for reporting incorrect calcium results when using the ABX PENTRA CALCIUM CP reagent.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Letter